Enterprise Value

9.187B

Cash

2.994B

Avg Qtr Burn

N/A

Short % of Float

4.42%

Insider Ownership

1.72%

Institutional Own.

97.02%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tyvaso (inhaled treprostinil) Details
Pulmonary Hypertension (PH) WHO Group 3

Approved

Quarterly sales

Remunity™ (treprostinil) Details
Pulmonary Hypertension (PH) WHO Group 1 (PAH)

Approved

Quarterly sales

Tyvaso DPI™ (inhaled treprostinil) Details
Pulmonary Hypertension (PH) WHO Group 1 / (PAH)Pulmonary Hypertension (PH) WHO Group 3

Approved

Quarterly sales

Tyvaso (inhaled treprostinil) Details
Progressive pulmonary fibrosis

Phase 3

Data readout

Tyvaso (inhaled treprostinil) Details
Pulmonary fibrosis, Idiopathic pulmonary fibrosis

Phase 3

Data readout

Phase 3

Data readout

Trevyent® (treprostinil sodium) Details
Pulmonary Hypertension (PH) WHO Group 1 (PAH)

Failed

Discontinued

Tyvaso (inhaled treprostinil) Details
Pulmonary hypertension, Chronic obstructive pulmonary disease

Failed

Discontinued